Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension

NCT02705755 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT02705755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02705755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Lead sponsor
Theravance Biopharma
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2017
Completion date
November 28, 2018
Enrollment
34 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hypotension, orthostatic, multiple system atrophy (msa) with orthostatic hypotension, neurogenic orthostatic hypotension, orthostatic hypotension, parkinson disease, parkinson disease with orthostatic hypotension, pure autonomic failure, pure autonomic failure with orthostatic hypotension